Oxford Nanopore Technologies plc New infectious disease partnership with bioMerieux
17 April 2023 - 4:00PM
RNS Non-Regulatory
TIDMONT
Oxford Nanopore Technologies plc
17 April 2023
Oxford Nanopore and bioMérieux
to enter into a strategic partnership agreement
to develop innovative infectious disease diagnostics
Oxford, UK and Marcy-l'Etoile, France, 17 April 2023: Oxford
Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore"), the
company delivering a new generation of nanopore-based molecular
sensing technology, and bioMérieux SA, a world leader in the field
of in vitro diagnostics, announced that they have teamed up to
improve health outcomes globally by exploring selected
opportunities to bring nanopore sequencing to the infectious
disease diagnostics market.
The companies are jointly exploring selected opportunities to
advance patient care by providing access to nanopore-based clinical
research and in vitro diagnostic (IVD) solutions.
Nanopore-based sequencing is a novel technology that enables
analysis of long DNA or RNA fragments. It works by monitoring
changes to an electrical current as nucleic acids are passed
through a protein nanopore. The resulting signal is decoded to
provide the specific DNA or RNA sequence. The unique real-time,
scalable features of this technology make it ideal for the rapid
and cost-effective characterisation of pathogens in clinical
samples.
Offering rapid and accurate identification of microbial
pathogens and associated antimicrobial resistance, Oxford Nanopore
is uniquely positioned to deliver nanopore-based sequencing
solutions that provide comprehensive results and reduce time to
results for infectious diseases research and diagnostic
applications.
Initial areas of collaboration will include a test for
determining antibiotic resistance of tuberculosis; an assay to
identify pathogens in normally sterile clinical samples; and
validating Oxford Nanopore's sequencing platform with BIOMÉRIEUX
EPISEQ(R) CS application for rapid infection outbreak monitoring in
patient-care settings.
Gordon Sanghera, Oxford Nanopore Technologies Chief Executive
Officer, commented: "We are pleased to partner with bioMérieux's
IVD expertise to add powerful new tools for the fight against
infectious disease. By offering rapid and accurate identification
of pathogens and associated antimicrobial resistance, at scale, we
hope to better equip the specialists for whom speed and access to
comprehensive data is key."
Alexandre Mérieux, bioMérieux Chairman and CEO, commented: "We
are excited to enter into a research partnership with Oxford
Nanopore in the field of infectious diseases. New technologies such
as sequencing hold promise to improve diagnostics and patient care;
our teams will collaborate in this direction."
[ENDS]
About Oxford Nanopore Technologies plc:
Oxford Nanopore Technologies' goal is to bring the widest
benefits to society through enabling the analysis of anything, by
anyone, anywhere. The company has developed a new generation of
nanopore-based sensing technology that is currently used for
real-time, high-performance, accessible, and scalable analysis of
DNA and RNA. The technology is used in more than 120 countries, to
understand the biology of humans, plants, animals, bacteria,
viruses and environments as well as to understand diseases such as
cancer. Oxford Nanopore's technology also has the potential to
provide broad, high impact, rapid insights in a number of areas
including healthcare, food and agriculture. For more information
please visit: www.nanoporetech.com
About bioMérieux:
PIONEERING DIAGNOSTICS
A world leader in the field of in vitro diagnostics since 1963,
bioMérieux is present in 45 countries and serves more than 160
countries with the support of a large network of distributors. In
2022, revenues reached EUR3.6 billion, with over 90% of sales
outside of France. bioMérieux provides diagnostic solutions
(systems, reagents, software and services) which determine the
source of disease and contamination to improve patient health and
ensure consumer safety. Its products are mainly used for diagnosing
infectious diseases. They are also used for detecting
microorganisms in food, pharmaceutical and cosmetic products. Learn
more: www.biomerieux.com
bioMérieux is listed on the Euronext Paris stock market.
Symbol: BIM - ISIN Code: FR0013280286
Reuters: BIOX.PA/Bloomberg: BIM.FP
CONTACTS
Oxford Nanopore
Media Relations Teneo (communication adviser to the
Company)
media@nanoporetech.com Tom Murray, Olivia Peters
Tel.: +44 (0) 20 7353 4200
Investor Relations
ir@nanoporetech.com OxfordNanoporeTechnologies@teneo.com
bioMérieux
Media Relations Investor Relations
Romain Duchez Franck Admant
Tel.: +33 (0)4 78 87 Tel.: +33 (0)4 78 87 20 00
21 99
media@biomerieux.com investor.relations@biomerieux.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAIFMMTMTMBTFJ
(END) Dow Jones Newswires
April 17, 2023 02:00 ET (06:00 GMT)
Oxford Nanopore Technolo... (LSE:ONT)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Nanopore Technolo... (LSE:ONT)
Historical Stock Chart
From May 2023 to May 2024